KR20140082053A - Composition having brain function and congnition enhancing activity comprising ginseng mixed herbal extracts, ginsenoside Rg2 and ginsenoside F2 - Google Patents

Abstract

The present invention relates to a composition for improving brain function and cognitive function, which comprises ginseng extract, extract of green tea leaf extract, extract of Seokchangpo, ginsenoside Rg2 and ginsenoside F2. The present invention relates to a composition for the prevention and treatment of degenerative brain diseases And as a memory enhancing agent.

Description

A composition for improving brain function and cognitive function comprising ginsenoside Rg2 and ginsenoside F2, and a composition for improving cognitive function comprising ginsenoside Rg2 and ginsenoside F2.

The present invention relates to a composition having brain and cognitive function improving activity, and more particularly, to a composition for improving brain function and cognitive function including ginseng extract, roots extract, Seokchang extract, ginsenoside Rg2 and ginsenoside F2 .

Alzheimer's disease (about 60-70%), vascular dementia, and dementia caused by certain brain and systemic diseases can be categorized by major causes of dementia.

Representative Alzheimer's disease is a disease caused by accumulation of beta amyloid (Aβ1-42) in the brain and neurotoxicity, which is known to be an important cause of the onset, and which damages the part that controls the judgment, memory, and language functions existing in the brain. Currently, there are tacrine (cognex) and donepezil (Aricept) for the treatment of senile dementia that have been approved by the US FDA. These are all substances that increase the activity of acetylcholine, a kind of neurotransmitter, which only slightly slows the progression of dementia in about 20-40% of patients.

Reminin (galantamine) not only blocks the action of acetylcholinesterase, but also has a dual effect of enhancing the action of acetylcholine at the nicotine receptor, which is ineffective. Donepezil selectively acts on acetylcholinesterase, is metabolized in the liver and excreted mainly in the kidneys. It was licensed by the US FDA in November 1996 and licensed by the Korean Food and Drug Administration in January 2001. It is sold as Aricept. In China, Huperzia A, which is used as a drug called Qian Ceng Ta, inhibits acetylcholinesterase. X-ray crystallography shows that the enzyme enters the active site of the enzyme and is stably positioned through numerous chemical bonds. Thereby preventing the decomposition reaction.

Ampakine activates the action of glutamate, the most common neurotransmitter in the brain. Cortex Pharmaceuticals and NIH are currently in clinical trials in the United States.

Vascular dementia (about 20-25%) is caused by repeated strokes (paralysis) resulting in damage to the brain. Repeated brain damage may be the most prominent symptom of dementia later on. In a model of ischemic brain disease, the amount of acetylcholine can be seen to be significantly lower in the hippocampus, which performs learning and memory, suggesting that parasympathetic nerves are suffering from functional disturbances due to intracerebral blood flow obstruction.

 In the case of animals other than humans, the role of the hippocampus is limited to spatial memory, and therefore it is most widely measured when measuring hippocampal function in experimental animals such as rats and mice Morris water maze task is the most widely used and avoidance task among various learning tasks. It has been reported that acethlcholine is depleted in the brain of patients with Alzheimer's disease and that scopolamine, an anticholinergic agent, causes memory loss similar to Alzheimer's disease. Scopolamine has been reported to inhibit passive conditioning avoidance, but there has been no report of its effect on active conditioning avoidance. In other words, it is a measure of how much the ginseng compound extract inhibits the spatial learning ability of the hippocampus CA1 by inducing neuronal cell death by ischemia.

Learning is a change in an organism created through experience, which affects the behavior of an organism and is called the memory of the long-lasting change. It refers to the ability to take it out into the conscious world when it is needed. This learning and memory is a neurotransmitter of brain cells that causes a morphological change in the synapse, indicating an increase in acetylcholine in the central cholinergic neurotransmitter system. Learning and memory have also been extensively studied through mouse experiments.

Ginseng is a perennial plant belonging to the genus Panax . The genus Panax is a perennial perennial perennial plant belonging to the genus Araliaceae . Panax ginseng (Panax ginseng), Panax quinquefolia, Panax notoginseng, Panax japonica, Panax trifolia, Panax pseudoginseng, Panax vietnamensis ). Especially, saponin having high content in Korean ginseng is ginsenosides Rb1, Rb2, Rc, Rd, Rg1, Re and the like. These saponin components exhibit various pharmacological effects. Depending on their structure, the types and strengths of the pharmacological effects are very different. The effect of ginseng on learning and memory has been revealed, and it is known that ginseng alleviates memory loss caused by damage to scopolamine-deficient animal models or hippocampus neurons.

Recently, studies on the antidepressant effect of raw paper have been made, but in the case of Jeonju, peel, and woody part, hypnotic action is used for insomnia. Saponin is a weakly toxic acid saponin and has hemolytic activity. The hemolysis of the skin is stronger than the woody part. Origin alcoholic extract inhibits gram-positive bacterium, dysentery, typhoid, and tuberculosis in vitro. Saponin of the ground stimulates the gastric mucosa and causes reflexive nausea of hardness. Patients with gastritis and gastric ulcers should avoid use.

It is said that Seok Changpo is a kind of medicine that treats the senses that are weakened by the customs, kills the white worms, treats the sickness with forgetfulness and forgetfulness, forgetful longevity, forgetfulness, tinnitus, , Brain fatigue, memory effect is highly effective.

Recently, attempts have been made to alleviate the decline in memory using extracts of Ginseng and Seokchangpo or their isolated components. However, there has been a problem in that the extracts and the isolated components thereof are inferior in activity to enhance memory.

The inventors of the present invention selected 13 kinds of medicinal drug candidates listed in the Dong-Bok-Gwan Newspaper (Gyeong-hak), and selected ginseng, ginseng, and seokchangpo as the preliminary experiments. And proceeded to the present invention.

The present inventors have repeatedly conducted studies to develop a safe herbal medicine composite material which helps the development of brain such as improvement of learning memory. As a result, it has been found that ginsenoside herb extract contains ginsenoside (Rg2 + F2) The present invention has been completed.

As described above, the present invention provides a new composite composition having brain function and cognitive function improving function, a pharmaceutical composition containing them, a health functional food, or a food additive.

The present invention provides a composition for improving brain function and cognitive function, comprising ginseng extract, extract of green tea extract, extract of Seokchangpo, ginsenoside Rg2 and ginsenoside F2.

The present invention also relates to a health functional food, a pharmaceutical composition, or a food additive which exhibits a brain function and a cognitive function improving effect, which comprises a composition containing the ginseng extract, native extract, Seokchang extract, ginsenoside Rg2 and ginsenoside F2 . The health functional food or pharmaceutical composition is preferably selected from the group consisting of tablets, capsules, powders, granules, liquids and pills.

The present invention relates to a novel composition comprising ginseng extract, an extract of green tea extract, a extract of Seokchang, a ginsenoside Rg2 and a ginsenoside F2 having brain function and cognitive function improving function, a pharmaceutical composition containing them, a health functional food and a food additive .

1 is a graph showing acetylcholinesterase inhibitory activity of the composition of Example 1 of the present invention.
FIG. 2 shows the results of measurement of the number of cells in the hippocampal CA1 region of the hippocampus of the control group treated with the physiological saline solution and the treated group administered with the composition of Example 1 of the present invention 7 days after inducing cerebral ischemia for 10 minutes with the normal control group Fig.
3 is a graph showing the results of an underwater maze test according to the first embodiment of the present invention.

The present invention provides a composition for improving brain function and cognitive function comprising ginseng extract, extract of leaf extract, extract of Seokchangpo, ginsenoside Rg2 and ginsenoside F2.

It is to be understood that in the present composition, the ginseng extract, the extract of Chrysanthemum gingko extract, and the extract of Chrysanthemum morifolium cortex contain each of the extracts of these herbal medicines and / or lyophilized powders of these extracts.

The ginseng extract, the extract of Seaweed Extract, and the extract of Seokchangpo are prepared by dissolving each herbal medicine with a C _1-4 alcohol such as methanol, ethanol, propanol, isopropanol or butanol, preferably a C _1-3 alcohol, more preferably methanol or ethanol, Is extracted by a conventional extraction method such as reflux extraction or ultrasonic extraction and concentrated under reduced pressure to obtain an alcoholic extract.

The composition of the present invention exhibits an effect of preventing or treating an excellent degenerative brain nervous system disease. To this end, the composition of the present invention may be used as an alcohol extract of ginseng extract, raw extract, and Seokchangpo extract. The extract may be fractionated with an organic solvent or water, The fractions prepared by the above method may be administered. Examples of the organic solvent for preparing the fractions include conventional solvents used for fractionating herbal medicine extracts such as butanol ( n- BuOH), hexane, ether, ethyl acetate (EtOAc), chloroform (CHCl ₃ ), dichloromethane, Benzene, acetone, preferably chloroform, ethyl acetate and butanol can be used. An extract powder obtained by freeze-drying the alcohol extract and / or the fraction may be used.

In the composition of the present invention, ginsenoside Rg2 and ginsenoside F2 can be extracted from ginseng by a conventional method, and commercially available substances can be purchased and used.

In the composition of the present invention, it is preferable that the weight ratio of the ginseng extract, the original extract, and the extract of Seokchonpo is 1: 10: 1 to 10: 1 to 10, preferably 1: 5: 1 to 5: In the composition of the present invention, the weight ratio of ginsenoside Rg2 and ginsenoside F2 is preferably 1 to 10: 1 to 10, and more preferably 1: 5 to 1: 5.

In the composition of the present invention, 0.0001 to 5% by weight, preferably 0.001 to 5% by weight, of ginsenoside Rg2 and ginsenoside F2, respectively, are added to 100 parts by weight of the ginseng extract, 0.01% to 3% by weight.

The composition of the present invention comprising the ginseng herbal medicine extract, ginsenoside Rg2 and ginsenoside F2 exhibits remarkably excellent brain function and / or cognitive function improving effect. Therefore, it can be used as a composition for the prevention and treatment of loss of memory, impairment of memory, in particular impairment of learning ability and / or impairment of memory capacity associated with loss of activity memory, dementia, forgetfulness, ischemic brain disease, Alzheimer's disease, .

The composition of the present invention can be formulated according to a conventional method by a known method in the pharmaceutical or food science field. In the manufacture of the formulations, it is preferred that the active ingredient is mixed with the carrier, diluted with the carrier, or encapsulated in a carrier in the form of a capsule, sachet or other container. Thus, formulations may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatine, capsules, sterile injectable solutions, sterile powders and the like.

As used herein, the term "health functional food" used in the present invention refers to a food containing a functional ingredient useful for the human body, Refers to a functional food such as a health food or beverage, yogurt, or cheese prepared and processed in the form of a capsule, a powder, a granule, a liquid agent, or a pill.

The composition of the present invention can be administered through various routes including oral, transdermal, subcutaneous, intravenous or muscular. A typical daily dose of the composition of the present invention may be in the range of 1 to 100 mg / kg body weight, preferably 1 to 10 mg / kg body weight, as an active ingredient, and may be administered once or several times in divided doses. However, the dosage is not intended to limit the scope of the invention in any way.

The composition of the present invention can also be used as a food additive or a food additive.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

Example  One

Test substance

The ginseng, raw paper and ginseng used in the present example were purchased from Kyungdong market, and ginsenosides Rg2 and F2 were purchased from SHENZHEN Chemstrong Scientific (Chaina).

1) Preparation of ginseng herbal medicine extract

1 kg of 4-year-old ginseng was crushed by a blender, 6 L of 70% ethanol aqueous solution was added, and the mixture was refluxed three times and immersed for 15 to 24 hours. Thereafter, the residue and the filtrate were separated using a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to prepare 120 g of ginseng.

2) Preparation of crude herbal medicine extract

6 kg of 70% ethanol-containing recipient (1 kg) was immersed in reflux for 3 times and immersed for 15 to 24 hours. Thereafter, the residue and the filtrate were separated by using a filter cloth and centrifugal separation, and the separated filtrate was concentrated under reduced pressure to obtain 180 g of the raw paper.

3) Preparation of Seokchangpo herbal medicine extract

1 kg of Seokchangpo was added with 6 L of 70% ethanol-containing drink, refluxed three times, and then immersed for 15 to 24 hours. Thereafter, the residue and filtrate were separated using a filter cloth and centrifugal separation, and the separated filtrate was concentrated under reduced pressure to obtain 180 g of Seokchangpo.

4) Preparation of the composition of Example 1 of the present invention

The composition of the present invention was prepared by thoroughly mixing 1 g of the ginseng extract, 0.8 g of the crude extract, 0.5 g of ginsenoside Rg2 and 0.5 mg of ginsenoside F2 in 1.2 g of Seokchang extract.

Each herbal medicine extract prepared in the above 1) to 3) was used as Comparative Examples 1 to 3.

Example  2 to 10

The composition of Examples 2 to 10 was prepared in the same manner as in Example 1 except that the ginseng extract, the raw extract and the Seokchang extract, and the ginsenoside Rg2 and ginsenoside F2 prepared in 1) to 3) .

Ginseng extract Origin Extract Seokchangpo extract Ginsenoside Rg2 Gin Senocide F2 Example 2 0.8 1.2 One 0.001 0.002 Example 3 2 One One 0.002 0.001 Example 4 One 0.2 0.8 0.0005 0.0003 Example 5 One 2 2 0.0003 0.0002 Example 6 5 One 5 0.0001 0.0001 Example 7 One 5 One 0.005 0.005 Example 8 One One One 0.0001 0.0005 Example 9 One 1.5 0.5 0.01 0.05 Example 10 One 0.5 1.5 0.05 0.01

Experimental Example  1: Ginseng herb extract of the present invention Gin Senocide Rg2 + Antioxidative experiments of F2

DPPH (1,1-diphenyl-2-picrylhydrazil) initiates oxidation to a purple radical. When DPPH solution was treated with the sample to be tested, the ability to remove radicals from the sample could be confirmed directly by color change.

To examine the degree of antioxidant activity of the herbal extract prepared in Example 1 and the herbal medicine extracts prepared in Comparative Examples 1 to 3, the free radicals produced by mixing the DPPH (Sigma, MI) solution and the herb extract Of the total amount of the water.

In Example 1, the extract samples were dissolved in distilled water or a solvent, and 20 μl of each sample was added to 96-well (Nunc, NY) at a final concentration of 0.01% to 1%, and 180 μl of 100 μM DPPH solution was added thereto. After that, the amount of the remaining DPPH was measured at 540 nm using an ELISA reader (Powerwave X, Bio-tec INC, VT). The degree of antioxidant activity was determined based on the negative control group consisting of DPPH, distilled water or solvent alone without adding the sample. As the absorbance was lower and the conversion value was lower, the free radical scavenging power was better.

Kinds 1 time Episode 2 Averaged value Conversion standard deviation O.D. Conversion value
(%) O.D. Conversion value
(%) Negative control group 0.34 100 0.33 100 100 0 Origin 0.29 85.29412 0.28 84.84848 85.0713012 0.315109974 Ginseng 0.213 62.64706 0.2 60.60606 61.6265597 1.44320368 Seokchangpo 0.178 52.35294 0.19 57.57576 54.9643494 3.693088893 Ginsenoside Rg2 0.31 91.17647 0.21 63.63636 77.4064171 19.47379638 Gin Senocide F2 0.21 61.76471 0.18 54.54545 58.1550802 5.104781575 The composition of Example 1 0.038 11.17647 0.029 8.787879 9.98217469 1.68898946

As can be seen from the above Table 2, it can be seen that the composition of Example 1 of the present invention exhibits remarkably excellent free radical scavenging power.

Experimental Example  2. Acetylcholine esterase  Measure inhibitory activity

The acetylcholinesterase (AChE) inhibitory activity of the composition of Example 1 of the present invention was measured using Ellman's coupled enzyme assay. The enzyme reaction was carried out in a 25 ° C 0.1 ° C thermostat. The reaction solution containing the substrate, Ellman's reagent and samples (20, 40, 60, 80, 100 mg / ml) was incubated for 4 minutes in a thermostatic chamber and incubated for 60 seconds with an enzyme solution (AChE 10 units / 10 μl) The absorbance was measured. The enzyme activity inhibitory effect of the sample was measured by using the absorbance (C.T.) of the control group containing the same amount of buffer instead of the test sample and the absorbance (S.T.) of the test group containing the test sample (FIG. The above experiments were carried out 4 times and then the inhibition rate of enzyme activity was calculated according to the following formula.

Inhibition rate (%) = 100- (ST / CT x 100)

As can be seen from Fig. 1, the composition of Example 1 of the present invention showed excellent acetylcholinesterase inhibitory activity.

Experimental Example  3. Neuronal cell  Evaluation of protective activity

An animal model of 4-vessel obstruction developed by Pulsinelli in 1979 was used. This model is a representative experimental animal model of cerebral ischemia. It temporarily blocks the blood supply to the brain and then reperfusion will damage the nerve cells in the hippocampus. After about 5-7 days, do. Experimental animals Wisters (5 weeks old) male rats weighing 170g were imported from Japan (SLC, Japan) and fed to the experimental environment for one week while supplying enough feed and water. The rats were anesthetized and fixed on a stereotaxic apparatus with a 30 ° tilt downward from the horizontal plane. The nose and mouth were covered with an anesthesia machine (Ohameda VMC / Boc Health Care, Cyprane, UK) with a plastic cone inhaler (cone). Anesthesia was initially maintained with 5% isoflurane in a mixture of nitrogen and oxygen (70% nitrogen, 30% oxygen) and then 1.5% isoflurane. The tail was fixed to the operating table and the cervical spine was extended, and a ring was made with a silicone tube on the common carotid artery to induce ischemia and reperfusion. In the next day, in order to block the microvascular circulation when inducing ischemia, the trachea, esophagus, external jugular vein and common carotid arteries are located at the back of the spinal cord and the common carotid arteries, cervical, and paravertebral muscles passed through, and then the wound was sutured with a surgical clip. The rats were then rotated and the posterior bony area was surgically removed. The cervical vertebra at the lower part of the occipital bone was operated using a surgical magnifying glass and the muscle was not injured toward the upper air hole (alar foramina). A fine electrocautery of less than 1 mm was inserted into the tunnel through the vertebral artery through the alar foramina of the cervical vertebra 1, and the vertebral artery was cauterized by intermittent current conduction. Using a surgical microscope, the vertebral artery in the tunnel passing through the bone was completely cauterized and confirmed to be closed, and then closed with a surgical clip. After 24 hours, the anterior surgical clip was removed and the whole carotid artery was tightened with an aneurysm clip for 10 minutes to induce ischemia. If the light reflexes were not lost within 1 minute, the neck suture was made firm and the rats without light reflection were excluded from this experiment because they did not cause complete bilateral parallel CA1 nerve damage. Ten minutes later, the aneurysm clip was removed from the common carotid artery and reperfused. After reperfusion, only the rats with 20 ± 5 minutes of loss of consciousness were used in the experiment. Rats that were awake or had been awakened after 25 minutes were also excluded from the study. Body temperature was monitored at intervals of 30 minutes until 6 hours after induction of ischemia

The lyophilizate of the composition of Example 1 was dissolved in distilled water and passed through a millipore membrane (0.22 μm, Millex-GV, U.S.A.) to make the sample sterile. Seven days after induction of cerebral ischemia by total cerebral ischemia, cerebral hippocampal CA1 cells were isolated from rats, and the above samples were administered at the concentrations of 30, 100 and 300 mg / kg, respectively. The results are shown in Fig. 2 (number of living cells in the CA1 region of the cerebral hippocampal tissue sham; normal rat control; N = 6).

As can be seen from FIG. 2, the number of neuronal cell survival of Example 1 was 103.3% as compared to the control group in which 300 mg / kg of Example 1 was administered. 290.0 ± 10.6 in the normal group, 29.3 ± 0.3 in the control group, 298.7 ± 3.3 in the 300 mg / kg administered group in Example 1, and 298.7 ± 3.3 in the positive control group, Respectively.

Experimental Example  4. For measuring spatial sensory perception ability Underwater labyrinth experiment

300 mg / kg of the composition of Example 1 was dissolved in physiological saline based on the body weight of the rats caused by cerebral ischemia and injected into the abdominal cavity for 4 days at intervals of 24 hours. In the control group, only physiological saline was administered by the same method. Behavioral measurements were performed from day 6 after 5 days of administration.

To test spatial perception ability, Morris water-maze method was used. The water temperature was maintained at 25 ± 1 ℃ for 5 days twice a day. For each test, place each animal at an arbitrary starting point to find a hidden platform. Wait for up to 120 seconds, and if no hidden platform is found, it is considered a failure and placed on the platform for 10 seconds. The latency, swimming speed, and swim trajectory for each platform were recorded and analyzed.

FIG. 3 shows the result of measuring the spatial perception ability of the composition administration group of Example 1 of the present invention and the control group not administered using the Morris water maze method.

As can be seen from FIG. 3, the residence time in the water of the group administered with 300 mg / kg of Example 1 was 8 seconds faster than that of the rats not administered with Example 1, and the spatial perception ability was superior to that of the control group Able to know. From the second day of the spatial perception ability test, the time of visiting the platform in the water in the group administered with Example 1 became shorter than that of the control group, and it was found that the difference becomes more conspicuous when the learning is repeated over time.

Example  6: Passive avoidance test ( Passive avoidance test )

Passive Avoidance Test was performed to see if it was effective in improving memory impairment. The experimental equipment used was a shuttle box (Gemini Avoidance System, San Diego Instruments, USA) with dimensions of 50, 15 and 40 cm in width, height and height. This box is divided into two rooms using a guillotine door. One room is made up of a light room and the other room is covered with a black cloth to make it a dark room. .

First, put the mouse in a bright room, turn on the light and open the partition door. The mouse enters the dark room within 20 seconds according to the instinct to find the dark place. As soon as the mouse moves into the dark room, the partition door closes. In this way, we measured the time from the light room to the dark room to the latency time. We conducted a training trial on the first day of the experiment to ensure that all mice were within 20 seconds.

The next day, put the rats that have been trained back in a bright room and turn on the lights to enter the dark room. At this time, an electric stimulus of 0.5 mA is applied for 3 seconds through an electronic grid installed on the floor of the dark room, and the mice are shocked on the soles of the feet. After 24 hours of this acquisition trial, rats were again placed in a bright room, turned on, and led to a dark room, where normal mice recalled the previous day's shock and were hesitant to enter the dark room (retention time ). The reaching time at this time was measured again with a maximum of 300 seconds, and the results are shown in Table 3 below.

Experimental sample retention time Control group 10.5 ± 0.6455 Origin 13.5 + 0.9465 Ginseng 13.725 ± 1.3573 Seokchangpo 12 ± 0.4082 Ginsenoside Rg2 14.75 ± 0.75 Gin Senocide F2 14.0 + 1.0801 Example 1 15.75 ± 1.25 Tacrine 15.25 + 0.9465

In the above experiment, a group administered with scopolamine (1.0 mg / kg), which is known to decrease memory through interference of neurotransmitter delivery, was used as a control group, and an hour later after administration of scopolamine, medicinal plants such as ginseng and tacrine Were measured. As a result, the group administered orally at a concentration of 30 mg / kg of tacrine as a positive control group showed a retention time of 15.25 ± 0.9465, and the retention time of Example 1 of the present invention was 15.75 ± 1.25, which was longer than that of the control group Respectively.

These results indicate that the composite composition of Example 1 of the present invention has the effect of improving the declining memory capacity of symptoms such as mild cognitive impairment or dementia.

Composition example

Composition example  1. Preparation of capsules

100 mg of the composition of Example 1

Lactose 100mg

Starch 93mg

Tangle 2 mg

Magnesium stearate qs

The above components are mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

Composition example  2. Preparation of capsules

200 mg of the composition of Example 1

Lactose 100mg

Starch 93mg

Tangle 2 mg

Magnesium stearate qs

The above components are mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.

Composition example  3. Liquid  Produce

200 mg of the composition of Example 2

Sugar 20g

20g per isomer

Lemon incense quantity

Purified water was added to the entire 100 ml

The above components are mixed according to a conventional method for preparing a liquid agent, filled in a 100 ml brown bottle, and sterilized to prepare a liquid agent.

Composition example  4. Liquid  Produce

300 mg of the composition of Example 3

Sugar 20g

20g per isomer

Lemon incense quantity

Purified water was added to the entire 100 ml

The above components are mixed according to a conventional method for preparing a liquid agent, filled in a 100 ml brown bottle, and sterilized to prepare a liquid agent.

Composition example  5. Manufacturing of beverages

A composition containing 5% by weight of the composition of Example 1, 0.05% by weight of food color, 0.05% by weight of orange essence, 5.0% by weight of fructose, 0.1% by weight of citric acid and 0.05% Next, purified water was added to prepare a beverage.

Claims (9)

A composition for improving brain function and cognitive function, comprising ginseng extract, extract of leaf extract, extract of Seokchangpo, ginsenoside Rg2 and ginsenoside F2. The composition for improving brain function and cognitive function according to claim 1, wherein the ginseng extract, the extract of Chrysanthemum morifolium, and the extract of Seokchangpo extract are C _{1 -4} alcohol extracts. [3] The composition for improving brain function and cognitive function according to claim 1, wherein the weight ratio of ginseng extract, rosemary extract, and Seokchangpo extract is 1 ~ 10: 1 ~ 10: 1-10. The composition for improving brain function and cognitive function according to claim 1, which comprises 0.001 to 5 parts by weight of ginsenoside Rg2 and ginsenoside F2, respectively, relative to 100 parts by weight of ginseng extract. 5. The method according to any one of claims 1 to 4, wherein said composition is for the treatment or prevention of memory loss, impaired learning and memory impairment associated with activity memory loss, dementia, forgetfulness, ischemic brain disease or Alzheimer's disease / RTI > A health functional food for improving brain function and cognitive function comprising the composition of any one of claims 1 to 4. The health functional food according to claim 6, wherein the health functional food is selected from the group consisting of tablets, capsules, powders, granules, liquids and pills. A pharmaceutical composition for improving brain function and cognitive function comprising the composition of any one of claims 1 to 4. A food additive for improving brain function and cognitive function comprising the composition of any one of claims 1 to 4.

Images